KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EPS (Weighted Average and Diluted) (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $1.13 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 969.23% year-over-year to $1.13, compared with a TTM value of $1.21 through Dec 2025, up 381.4%, and an annual FY2025 reading of $1.21, up 381.4% over the prior year.
  • EPS (Weighted Average and Diluted) was $1.13 for Q4 2025 at Biocryst Pharmaceuticals, up from $0.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.13 in Q4 2025 and bottomed at -$0.89 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.01, with a median of -$0.06 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 85.34% in 2024, then surged 969.23% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.89 in 2023, then surged by 85.34% to -$0.13 in 2024, then surged by 969.23% to $1.13 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BCRX at $1.13 in Q4 2025, $0.06 in Q3 2025, and $0.02 in Q2 2025.